Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market

This article originally appeared on our sister site, Optometry Times.

Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved the TECNIS PureSee intraocular lens (IOL), an extended depth of focus (EDOF) lens intended for use in cataract surgery. The company said in a news release the TECNIS PureSee IOL will be available to patients in the US later this year.¹

“Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs,” said Peter Menziuso, company group chairman of Vision at Johnson & Johnson, in the release. “Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”

Cataracts develop naturally with age and can make activities such as reading, driving, and recognizing faces more difficult. Cataract surgery removes the clouded natural lens and replaces it with an artificial lens. The company said the TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia, which occurs when the eyes gradually lose the ability to see objects clearly at close range.¹

According to the company, the TECNIS PureSee IOL is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity. Contrast sensitivity refers to the ability to distinguish an object from its background, which is particularly important in low-light or foggy conditions. Johnson & Johnson said the lens maintains contrast sensitivity comparable to an aspheric monofocal IOL while providing an extended range of vision.¹

Built on the TECNIS platform, the lens combines advanced optics with proprietary materials to provide distance and intermediate vision, with some near vision. The company reported that 97% of patients experienced no very bothersome visual disturbances and that the lens can reduce reliance on glasses

after surgery.¹

The TECNIS PureSee IOL expands Johnson & Johnson’s surgical vision portfolio, which includes TECNIS Odyssey IOL, a Full Visual Range (FVR) IOL, and TECNIS Eyhance IOL, a monofocal lens designed to slightly extend depth of focus.¹

Reference

1. Johnson & Johnson announces FDA approval of TECNIS PureSee intraocular lens, a breakthrough solution for US cataract patients. News release. Johnson & Johnson. March 12, 2026. Accessed March 12, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients